A Phase II Preventative Trial of DFMO in Patients with High Risk Neuroblastoma in Remission Prevents Relapse and Increases Overall Survival
Giselle L. Saulnier Sholler, William Ferguson, Genevieve Bergendahl, Jeffrey P. Bond, William Roberts, Randal K. Wada, Don Eslin, Javier Oesterland, Jessica Foley, Deanna Mitchell, Nehal S. Parikh, Kathleen Neville, Francis[...]
HDAC inhibitor panobinostat as a selective agent, synergizes with chemotherapeutics in medulloblastoma and neuroblastoma
Witte A, Durston M, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G, HDAC inhibitor panobinostat as a selective agent, synergizes with chemotherapeutics in medulloblastoma and neuroblastoma. American Association of Cancer Research[...]
BKM120 is cytotoxic in neuroblastoma targeting the PI3K pathway
Pomaville M, Zhao P, DeCou S, Nagulapally AB, Bond J, Saulnier Sholler G, BKM120 is cytotoxic in neuroblastoma targeting the PI3K pathway. American Association of Cancer Research (AACR) Annual Meeting, 2016. New Orleans, LA
Bortezomib, a proteasome inhibitor, synergizes with DFMO to inhibit neuroblastoma cell proliferation via the reversal of the LIN28/Let-7 axis
Rich M, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G, Bortezomib, a proteasome inhibitor, synergizes with DFMO to inhibit neuroblastoma cell proliferation via the reversal of the LIN28/Let-7 axis. American Association[...]
Autologous antibodies that bind neuroblastoma cells
Sun Y, Sholler GS, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Nov;426:35-41; PMID:26210205
Tolcapone, a catechol-O-methyltransferase inhibitor, alone and in combination with oxaliplatin induces cell death in neuroblastoma
Hayes D, Zhao P, Nagulapally AB, Bond J,2, Saulnier Sholler G, Tolcapone, a catechol-O-methyltransferase inhibitor, alone and in combination with oxaliplatin induces cell death in neuroblastoma. American Association of Cancer Research (AACR)[...]
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma
Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Sholler G, A Phase 1 Trial of[...]
Autologous antibodies that bind neuroblastoma cells
Sun Y, Sholler GS, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Jul 23. pii: S0022-1759(15)30025-9. doi: 10.1016/j.jim.2015.07.009. [Epub ahead of print]
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
Saulnier Sholler G, Gerner EW, Bergendahl G, MacArthur RB, Vander Werff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D,[...]
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga[...]